A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasis.

A recent Phase IIa clinical trial found that the ChAd63-KH vaccine was safe and immunogenic in Sudanese patients with post kala-azar dermal leishmaniasis (PKDL). However, a new Phase IIb trial aimed to assess the therapeutic efficacy of the vaccine as a stand-alone treatment. The trial enrolled 86 participants with uncomplicated PKDL and administered either ChAd63-KH or a placebo. After 90 days, there was no significant difference in clinical improvement between the vaccine and placebo groups. Further studies are needed to determine if the vaccine could be effective with different dosing regimens or in combination with other treatments. [Extracted from the article]

Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)